Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia
Manuscript Number:
19-1173R1
Author(s):
Thomas C. Baddeley, Peter Bentham, Luc Bracoud, Harish Ganesan, Serge Gauthier, Jeffrey Hammel, Jiri H. Hardlund, Charles R. Harrington, Jianping Jia, Christopher Kipps, Karin A. Kook, Hans J. Moebius, Alison Murray, Gernot Riedel, Christopher M. Rubino, Björn O. Schelter, Helen Shiells, Roger T. Staff, John M.D. Storey, Vesna Vuksanovic, Claude M. Wischik, Damon J. Wischik
Disclosures
Thomas C. Baddeley
Equity:
A small number of shares in TauRx
Sponsors:
Salary, Head of Analytical Chemistry and DMPK for TauRx
Patents/Royalties
Named author on several patents with TauRx
Peter Bentham
Sponsors:
Consultant Clinical Advisor
Luc Bracoud
Nothing to Disclose
Harish Ganesan
Nothing to Disclose
Serge Gauthier
Consulting Fees:
TauRx, BI, Biogen, scientific advisory boards
Jeffrey Hammel
Nothing to Disclose
Jiri H. Hardlund
Sponsors:
I was employed by TauRx Therapeutics Ltd.during the study reported.
Charles R. Harrington
Equity:
Shares in TauRx Therapeutics Ltd.
Sponsors:
Employed as Chief Scientific Officer of TauRx Therapeutics Ltd.
Patents/Royalties
I am a named inventor on several patents in the field of neurodegenerative diseases and therapeutic approaches. Patents owned by WisTa Laboratories Ltd., an affiliate of TauRx Therapeutics Ltd.
Grants
Agency:
TauRx Therapeutics Ltd
Dates:
Since 2002
Jianping Jia
Nothing to Disclose
Christopher Kipps
Nothing to Disclose
Karin A. Kook
Consulting Fees:
Consultant to numerous pharmaceutical companies, including TauRx, and a paid member of one Corporate Advisory Board.
Hans J. Moebius
Patents/Royalties
Co-inventor on 2 patents relating to therapy of BPSD in Alzheimer's Disease. No royalties. Acting / CMO for two biotech start-ups, none related to treatment of FTD.
Alison Murray
Patents/Royalties
Wischik, C. M., Harbaran, D. V., Riedel, G., Deiana, S., Goatman, E. A., Wischik, D. J., Murray, A. D. & Staff, R. T. Phenothiazine compounds for treating mild cognitive impairment. 15 Dec 2015 17 Jun 2008 19 Jun 200760/945006. Patent
Grants
Agency:
Canon Medical Research Europe and Philips Healthcare
Dates:
01/02/2019-31/01/2022
Gernot Riedel
Nothing to Disclose
Christopher M. Rubino
Consulting Fees:
ICPD received consulting fees from TauRx to perform the PK-PD analyses described in this manuscript.
Björn O. Schelter
Consulting Fees:
I am paid consultant and subject matter expert for TauRx, the sponsor of the study, as well as GentingTauRxDiagnostics. I consult in various aspects of data analytics and biostatistics.
Patents/Royalties
I am co-inventor on various patents related to my TauRx/GentingTauRxDiagnostics role.
Grants
Agency:
WistaLab
Dates:
01 Jan 2019 - 31 Dec 2021
Helen Shiells
Sponsors:
Employee of TauRx Therapeutics Ltd.
Roger T. Staff
Consulting Fees:
I have received some consulting income from TauRx Ltd
John M.D. Storey
Equity:
Hold stock in TauRx Therapeutics Ltd.
Sponsors:
Chief Technical Officer for TauRx Therapeutics Ltd.
Patents/Royalties
Patents on chemical synthesis of compounds as therapeutic agents for treatment of Alzheimer's disease and other neurodegenerative disorders. All rights assigned to WisTa Laboratories, an affiliate of TauRx.
Grants
Agency:
TauRx Therapeutics Ltd
Dates:
Since 2002
Vesna Vuksanovic
Nothing to Disclose
Claude M. Wischik
Equity:
Equity in TauRx Therapeutics Ltd.
Sponsors:
Executive Chair, TauRx Therapeutics Ltd.
Patents/Royalties
Patents related to the treatment of Alzheimer's disease and related disorders.
Grants
Agency:
TauRx Therapeutics Ltd
Dates:
Since 2002
Damon J. Wischik
Patents/Royalties
PCT international applications: WO08/155533, WO09/044127, WO09/060191